An AstraZeneca, Bristol Myers Squibb merger could create a cancer-drug giant, but analysts call it ‘odd’. AstraZeneca shares were slumping while Bristol-Myers Squibb’s stock was jumping on Monday on reported deal talks.
A apuração publicada por www.marketwatch.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: AstraZeneca shares were slumping while Bristol-Myers Squibb’s stock was jumping on Monday on reported deal talks. But the big question is why these two pharmaceutical giants would want to come together in the first place.
- Ponto de atenção: astrazeneca.
- Ponto de atenção: bristol.
- Ponto de atenção: myers.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Investimentos.
